Biropepimut-S is under clinical development by Gliknik and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Biropepimut-S’s likelihood of approval (LoA) and phase transition for Head And Neck Cancer Squamous Cell Carcinoma took place on 27 Jan 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Biropepimut-S Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Biropepimut-S is under development for the treatment of head and neck squamous cell carcinoma and multiple myeloma. It is administered through intramuscular and intravenous route. The drug candidate is a cancer vaccine. The vaccine designed to target human melanoma antigen A3 (MAGE-A3).
It was under development for the treatment of squamous cell cancer of the oral cavity.G M T
Gliknik is a bio pharmaceutical company that develops therapies for patients suffering from cancer and immune disorders. The company’s pipeline products include biropepimut-S (GL-0817) and GL-2045. Its biropepimut-S is an engineered peptide immunomodulator targeted against important epitopes within the cancer protein MAGE-A3. Gliknik designs recombinant GL-2045 to mimic the structure and efficacy of the very small and variable portion of the pooled human blood product IVIG, which is an active fraction in treating autoimmune disorders. The company partners with pharmaceutical industries. Gliknik is headquartered in Baltimore, Maryland, the US.
Quick View Biropepimut-S LOA Data
|Highest Development Stage|